On September 25, NMPA released information on the delivery of drug certification documents, and the rivastigmine transdermal patch of Beijing Taide Pharmaceutical Co., Ltd. (hereinafter referred to as "Tide Pharmaceutical"), a subsidiary of Sino Biopharmaceutical, was approved for marketing. It is understood that the drug can be used to treat mild to moderate Alzheimer's disease.
Forecasts of the development trend of Alzheimer's disease and other forms of dementia in China show that in 2030, 2040 and 2050, the number of AD patients in the population aged 60 and above in China will reach 19.11 million, 24.71 million and 27.65 million respectively. Under the influence of multiple factors such as the accelerated aging trend of the population in China and the increasing prevalence of major cardiovascular diseases and related factors, the prevalence and number of patients with Alzheimer's disease have also shown an increasing trend year by year.

Rivastigmine is an acetylcholinesterase inhibitor that improves cognitive functions such as memory and thinking by increasing the amount of certain natural substances in the brain and amplifying the communication channels between nerve cells. It can be used to treat mild to moderate Alzheimer's disease and Parkinson's disease. The drug is mainly administered orally or via transdermal patch, and the transdermal patch can reduce the occurrence of side effects such as nausea and vomiting.
In October 2023, Luye Pharma's Class 5.1 imported product "Rivastigmine Transdermal Patch (2 times/W)" was approved for marketing, while the one-day transdermal patch was approved for marketing in China in 2022. Taide Pharmaceutical's Rivastigmine Transdermal Patch is the first domestically produced generic drug approved for marketing in China.

https://news.yaozh.com/archive/44264.html